Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 07:06 am Purchase | 2025-06-30 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 7,857,347 15.000% | 2,500,000 (+46.66%) | Filing History |
| 2025-08-12 09:07 am Purchase | 2025-06-30 | 13G | TScan Therapeutics, Inc. TCRX | Adage Capital Management, L.P. | 1,350,000 2.520% | 1,350,000 (New Position) | Filing History |
| 2025-07-16 7:02 pm Sale | 2025-06-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 958,373 1.800% | -1,867,450 (-66.09%) | Filing History |
| 2025-05-15 4:40 pm Purchase | 2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,263,541 9.990% | 190,538 (+3.76%) | Filing History |
| 2025-05-15 2:19 pm Sale | 2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX | EcoR1 Capital, LLC | 662,833 1.300% | -4,337,167 (-86.74%) | Filing History |
| 2025-04-24 09:12 am Sale | 2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 2,825,823 5.400% | -1,807,453 (-39.01%) | Filing History |
| 2025-02-14 4:33 pm Sale | 2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 3,602,700 6.900% | -1,721,444 (-32.33%) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 5,357,347 10.900% | 132,747 (+2.54%) | Filing History |
| 2025-02-12 09:38 am Sale | 2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,500,000 7.130% | -400,000 (-10.26%) | Filing History |
| 2024-11-14 4:40 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% | 658,093 (+14.91%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% | 736,110 (+16.04%) | Filing History |
| 2024-11-14 3:05 pm Sale | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | Cormorant Asset Management, LP | 0 0.000% | -2,500,000 (Position Closed) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 0 (Unchanged) | Filing History |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 3,366,088 (+265.63%) | Filing History |
| 2024-04-29 4:02 pm Purchase | 2024-04-19 | 13G | TScan Therapeutics, Inc. TCRX | Cormorant Asset Management, LP | 2,500,000 5.150% | 2,500,000 (New Position) | Filing History |
| 2024-04-23 4:25 pm Purchase | 2024-04-19 | 13D | TScan Therapeutics, Inc. TCRX | BAKER BROS. ADVISORS LP | 2,828,938 6.100% | 35,000 (+1.25%) | Filing History |
| 2024-02-14 4:45 pm Purchase | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% | 2,488,225 (+118.50%) | Filing History |
| 2024-02-09 4:08 pm Unchanged | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | GV 2017, L.P. | 1,077,080 2.500% | 0 (Unchanged) | Filing History |
| 2024-02-08 06:02 am Purchase | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Pitango HealthTech Fund I L.P. | 2,079,985 4.300% | 1,000,000 (+92.59%) | Filing History |
| 2024-02-07 07:45 am Sale | 2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,900,000 8.960% | -100,000 (-2.50%) | Filing History |